Genmab

About Genmab

Genmab is an international biotechnology company with a core purpose guiding its unstoppable team to strive towards improving the lives of patients through innovative and differentiated antibody therapeutics. For more than 20 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged transactional research and data sciences, which has resulted in a proprietary pipeline including bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. To help develop and deliver novel antibody therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. By 2030 Genmab's vision is to transform the lives of people with cancer and other serious diseases with Knock-Your-Socks-Off (KYSO) antibody medicines.

How we Operate

Team: Flexible and adaptive infrastructure

Translational Research & Data Science: Key to accelerating development & ensuring the right therapies get to the right patients

Research: Track record of success and investing for tomorrow

Development: Scaling up capabilities to expand from early-to-late stage

Commercialization: Next step in our evolution

Enabling Functions: support growth and manage risk

Strong financials: Growing recurring revenues and focused investment

Collaboration: Across innovation ecosystem of pharma, biotech & academia, drives our business forward

At-a-glance

Genmab's Growing Organization & Growing Presence



Our Strengths & Differentiators

- **World-Class** antibody biology knowledge and deep insight into disease targets
- **Discovery and development engine** with proprietary technologies that allow us to build a world-class pipeline
- **In-house expertise** with solid track record of building successful strategic partnerships
- **Robust pipeline** of potential best-in-class and first-in-class therapies
- **Experienced, diverse** leadership team

Operational

6 **Approved Medicines Including Genmab's Innovation**

Tivdak® in partnership with Seagen, first Genmab owned product on market
DARZALEX,® RYBREVANT®and TECVAYLI® discovered and/or developed & marketed by Janssen
Kesimpta®developed & marketed by Novartis
TEPEZZA®developed & marketed by Horizon Therapeutics

4 **Proprietary* Technologies**

DuoBody®platform, HexaBody®platform, DuoHexaBody® platform & HexElect® platform

9 **Proprietary* Antibody Products in Clinical Development**

Tisotumab vedotin, epcoritamab, DuoBody-PD-L1x4-1BB (GEN1046/BNT311), DuoBody-CD40x4-1BB (GEN1042/BNT312), HexaBody-CD27 (GEN1053/BNT313), GEN1056 (BNT322), DuoHexaBody-CD37 (GEN3009), HexaBody-CD38 (GEN3014), DuoBody-CD3xB7H4 (GEN1047)

41 **Cumulative INDs since 1999**

Created by Genmab or with Genmab's technologies

2022 Financials (DKK)

194B	6,357M	14,595M	8,238M
Year-end market cap	Operating Profit	Revenue	Operating Expenses 68% in R&D

Our Purpose

Our unstoppable team will improve the lives of patients through innovative and differentiated antibody therapeutics

Our Vision

By 2030, our KYSO antibody medicines are fundamentally transforming the lives of people with cancer and other serious diseases

Our Values

- Passion for Innovation
- Determined - being the best at what we do
- Integrity - we do the right thing
- We work as one team & respect each other

Our Strategy

- Focus on core competence
- Turn science into medicine
- Build a profitable and successful biotech

Strong Pipeline of Potential 1st-in-class/Best-in-class Product Candidates

Genmab's Proprietary[1] Products

Product	Target	Developed By	Disease Indication	Most Advanced Development Phase
				Pre-clin / 1 / 1/2 / 2 / 3
Tisotumab vedotin	TF	Co-dev. Genmab/ Seagen	Cervical cancer	
			Solid tumors	
Epcoritamab	CD3, CD20	Co. dev. Genmab/ AbbVie	RR DLBCL	
			RR FL (combo)	
			ND DLBCL (combo)	
			B-NHL	
			B-NHL (combo)	
			RR CLL & Richter's Syndrome	
			iNHL, pediatric	
DuoBody-PD-L1x4-1BB (GEN1046/BNT311)	PD-L1, 4-1BB	Co-dev. Genmab/ BioNTech	NSCLC	
			Solid tumors	
DuoBody-CD40x4-1BB (GEN1042/BNT312)	CD40, 4-1BB	Co-dev. Genmab/ BioNTech	Solid tumors	
DuoHexaBody-CD37 (GEN3009)	CD37	Genmab	Hem. malignancies	
HexaBody-CD38 (GEN3014)	CD38	Genmab[2]	Hem. malignancies	
DuoBody-CD3xB7H4 (GEN1047)	CD3, B7H4	Genmab	Solid tumors	
HexaBody-CD27 (GEN1053/BNT313)	CD27	Co-dev. Genmab/ BioNTech	Solid tumors	
GEN1056 (BNT322)	Undisclosed	Co-dev. Genmab/ BioNTech	Solid tumors	

Programs Incorporating Genmab's Innovation and Technology, ≥Phase 2 Development[3]

Product	Target	Discovered and/or Developed By	Disease Indication	Most Advanced Development Phase
				Pre-clin / 1 / 1/2 / 2 / 3
Daratumumab	UltiMab®	Janssen	MM	
			AL Amyloidosis	
Ofatumumab	UltiMab	Novartis	RMS	
Teprotumumab	UltiMab	Horizon Therapeutics	Thyroid eye disease	
Amivantamab	DuoBody	Janssen	NSCLC	
			Adv. or metastatic gastric or esophageal cancer	
			Adv. or metastatic colorectal cancer	
Teclistamab	DuoBody	Janssen	MM	
Talquetamab	DuoBody	Janssen	RRMM	
Inclacumab	UltiMab	Pfizer (Global Blood Therapeutics	Vaso-occlusive crises in sickle cell disease	
Mim8	DuoBody	Novo Nordisk	Hemophilia A	
Ordesekimab	UltiMab	Provention Bio	Celiac disease	
Lu AF82422	UltiMab	Lundbeck	Multiple system atrophy	

Proprietary Technologies Allow us to Build a World-class Pipeline

DuoBody Platform
- -Bispecific antibody technology platform
- -Potential in cancer, autoimmune, infectious, cardiovascular, central nervous system diseases and hemophilia
- -Multiple commercial & research collaborations

HexaBody Platform
- -Enhanced potency antibody technology platform
- -Broadly applicable technology that builds on natural antibody biology

DuoHexaBody Platform
- -Antibody technology that combines **DuoBody** and **HexaBody** platforms
- -Creates bispecific antibodies with target mediated enhanced potency

HexElect Platform
- -Antibody technology platform inspired by **HexaBody** platform
- -Combines dual targeting with enhanced selectivity & potency

Executive Management
- Jan G. J. van de Winkel, Ph.D., President & CEO
- Anthony Pagano, EVP & CFO
- Judith Klimovsky, M.D., EVP & CDO
- Anthony Mancini, EVP & COO
- Tahamtan Ahmadi, M.D., Ph.D., EVP & CMO
- Birgitte Stephensen, EVP & CLO
- Christopher Cozic, EVP & CPO
- Martine J. van Vugt, Ph.D., EVP & CSO

Notes
*Tisotumab vedotin 50:50 partnership with Seagen; epcoritamab 50:50 partnership with AbbVie; DuoBody-PD-L1x4-1BB, DuoBody-CD40x4 -1BB, HexaBody-CD27 and GEN1056 50:50 partnership with BioNTech; HexaBody-CD38, exclusive worldwide license and option agreement with Janssen Biotech, Inc.
1Certain product candidates in development with partners, as noted
2Genmab is developing HexaBody-CD38 in an exclusive worldwide license and option agreement with Janssen Biotech, Inc.
3Products discovered and/or developed and marketed by others incorporating Genmab technology and innovation.

This document contains forward looking statements that involve significant risks and uncertainties. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab's most recent Annual Report on form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. May 10, 2023